Skip to main content

Table 1 Completed phase III trials with targeted agents in advanced gastric cancer

From: Targeted and novel therapy in advanced gastric cancer

Targeted pathway Agent Trial Selection biomarker/trial design Overall survival benefit/months (experimental versus control)
HER2 Trastuzumab ToGA/1st-line [13] HER2/chemotherapy with or without trastuzumab Positive (HR 0.74)/13.8 versus 11.1
Trastuzumab HELOISE/1st-line phase IIIb [14] HER2/chemotherapy with standard-dose versus high-dose trastuzumab Negative (HR 1.24)/12.5 versus 10.6
Trastuzumab/pertuzumab JACOB/1st-line [21] HER2/trastuzumab plus chemotherapy with pertuzumab or placebo Negative (HR 0.84)/17.5 versus 14.2
Trastuzumab emtansine (T-DM1) GATSBY/2nd-line [29] HER2/T-DM1 versus taxane Negative (HR 1.15)/7.9 versus 8.6
Lapatinib LoGIC/1st-line [41] HER2/chemotherapy with lapatinib or placebo Negative (HR 0.91)/12.2 versus 10.5
Lapatinib Tytan/2nd-line [43] HER2/paclitaxel with or without lapatinib Negative (HR 0.84)/11.0 versus 8.9
Angiogenesis Bevacizumab AVAGAST/1st-line [75] None/chemotherapy with bevacizumab or placebo Negative (HR 0.87)/12.1 versus 10.1
Bevacizumab AVATAR/1st-line [78] None/chemotherapy with bevacizumab or placebo in Chinese patients Negative (HR 1.11)/10.5 versus 11.4
Ramucirumab RAINFALL/1st-line [66] HER2(−)/chemotherapy with ramucirumab or placebo Negative (HR 0.96)/11.2 versus 10.7
Ramucirumab RAINBOW/2nd-line [61] None/paclitaxel with ramucirumab or placebo Positive (HR 0.807)/9.6 versus 7.4
Ramucirumab REGARD/2nd and 3rd-line [60] None/ramucirumab versus placebo Positive (HR 0.776)/5.2 versus 3.8
Apatinib NCT01512745/3rd-line [73] None/apatinib versus placebo Positive (HR 0.71)/6.5 versus 4.7
PD-1/PD-L1 Nivolumab ATTRACTION 2/3rd-line [102] None/nivolumab versus placebo in Asian patients Positive (HR 0.63)/5.26 versus 4.14
Pembrolizumab KEYNOTE-061/2nd-line [96] PD-L1/pembrolizumab versus paclitaxel Negative (HR 0.82)/9.1 versus 8.3
Pembrolizumab KEYNOTE-181/2nd-line [97] PD-L1/pembrolizumab versus chemotherapy Positive (HR 0.69)/9.3 versus 6.7 in PD-L1 ≥ 10%
Pembrolizumab KEYNOTE-062/1st-line [98] PD-L1 & HER2(−)/pembrolizumab alone or pembrolizumab plus chemotherapy versus chemotherapy alone Noninferior for Pembrolizumab (HR 0.91)/10.6 versus 11.1. Negative for Pembrolizumab and chemotherapy (HR 0.85)/12.5 versus 11.1
Avelumab JAVELIN Gastric 300/3rd-line [103] None/avelumab versus chemotherapy Negative (HR 1.1)/4.6 versus 5.0
DNA TAS-102 TAGS/3rd-line [106] None/TAS-102 versus placebo Positive (HR 0.69)/5.7 versus 3.6
EGFR Cetuximab EXPAND/1st-line [120] None/chemotherapy with or without cetuximab Negative (HR 1.03)/9.4 versus 10.7
Panitumumab REAL3/1st-line [121] None/chemotherapy with or without panitumumab Negative (HR 1.37)/8.8 versus 11.3
STAT3 Napabucasin BRIGHTER/2nd-line [132] None/paclitaxel with napabucasin or placebo Negative (HR 1.01)/6.93 versus 7.36
PARP Olaparib GOLD/2nd-line [137] None/paclitaxel with olaparib or placebo Negative (HR 0.79 [97.5% CI 0.63–1.00])/8.8 versus 6.9
MMP-9 Andecaliximab GAMMA-1/1st-line [138] HER2(−)/mFOLFOX6 with andecaliximab or placebo Negative (HR 0.93)/12.5 versus 11.8
MET Onartuzumab METGastric/1st-line) [144] MET and HER2(−)/mFOLFOX6 with onartuzumab or placebo Negative (HR 0.82)/11.0 versus 11.3
Rilotumumab RILOMET-1/1st-line) [143] MET and HER2(−)/chemotherapy with rilotumumab or placebo Negative (HR 1.34)/8.8 versus 10.7
mTOR Everolimus GRANITE-1/3rd-line) [140] None/everolimus versus placebo Negative (HR 0.90)/5.4 versus 4.3
  1. HER2 human epidermal growth factor receptor 2, HR hazard ratio, PD-1 programmed death-1, PD-L1 programmed death ligand 1, DNA deoxyribonucleic acid, EGFR epidermal growth factor receptor, STAT3 signal transducer and activator of transcription 3, PARP poly (ADP-ribose) polymerase, MMP-9 matrix metalloproteinase 9, mFOLFOX6 5-fluorouracil/leucovorin/oxaliplatin, MET mesenchymal–epithelial transition, mTOR mammalian target of rapamycin